Business Development
Partnerships are an integral part of the business of Statens Serum Institut.
Business Development in the Division of Vaccine is focused on identifying, entering and maintaining successful partnerships within our key areas of interest:
We are open to mutually beneficial partnerships with academia, biotech companies and pharmaceutical industry in order to establish both scientific collaborations and value maximizing commercial partnerships.
We are actively seeking out-licensing opportunities for our proprietary technologies and we are continuously searching for innovative technologies supplementing our existing technologies and R&D programs.
Currently, SSI is part of several global alliances, e.g. out-licensure of tuberculosis antigens to several key players within tuberculosis in-vitro diagnostics (e.g. Cellestis Ltd and Oxford Immunotec), as well as a partnership with Sanofi-Pasteur for the development of a tuberculosis vaccine.
N.B. for enquiries relating to SSI’s HIV vaccine development program please refer to Business Development Microbiology
Last revised 21 December 2011